Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine ...